公开(公告)号：US20150087585A1

公开(公告)日：2015-03-26

申请号：US14384508

申请日：2013-03-26

Applicant: Pfizer Inc.

Inventor： Kay Ahn ,  Markus Boehm ,  Shawn Cabral ,  Philip A. Carpino ,  Kentaro Futatsugi ,  David Hepworth ,  Daniel W. Kung ,  Suvi Orr ,  Jian Wang

IPC: C07D471/04 ,  A61K45/06 ,  A61K31/52 ,  A61K31/5377 ,  A61K31/538 ,  C07D487/04 ,  A61K31/437 ,  A61K31/506

CPC classification number: C07D471/04 ,  A61K31/437 ,  A61K31/506 ,  A61K31/52 ,  A61K31/5377 ,  A61K31/538 ,  A61K45/06 ,  C07D487/04 ,  C07D519/00

Abstract: Derivatives of purine, 3H-imidazo[4,5-b]pyrimidine and 1H-imidazo[4,5-d]pyrazine of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.

Abstract translation: 抑制二酰基甘油酰基转移酶2（DGAT2）活性的式I的嘌呤衍生物，3H-咪唑并[4,5-b]嘧啶和1H-咪唑并[4,5-d]吡嗪及其在治疗疾病中的用途 本文描述了与动物相连的动物。

公开(公告)号：US20210315900A1

公开(公告)日：2021-10-14

申请号：US17349916

申请日：2021-06-17

Applicant: PFIZER INC.

Inventor： Fady Makram Louiz Ibrahim ,  Matthew Patrick Mullarney ,  Ravi M. Shanker ,  Barbara Rodriguez Spong ,  Jian Wang

IPC: A61K31/519 ,  A61K9/20 ,  A61K9/28 ,  A61K47/12 ,  A61K31/4439

Abstract: The present invention relates to solid dosage forms of palbociclib comprising a water-soluble acid. The dosage forms described herein have desirable pharmacokinetic characteristics.

公开(公告)号：US09296745B2

公开(公告)日：2016-03-29

申请号：US14384508

申请日：2013-03-26

Applicant: Pfizer Inc.

Inventor： Kay Ahn ,  Markus Boehm ,  Shawn Cabral ,  Philip A. Carpino ,  Kentaro Futatsugi ,  David Hepworth ,  Daniel W. Kung ,  Suvi Orr ,  Jian Wang

IPC: C07D471/04 ,  A61K45/06 ,  C07D487/04 ,  C07D519/00 ,  A61K31/437 ,  A61K31/506 ,  A61K31/52 ,  A61K31/5377 ,  A61K31/538

CPC classification number: C07D471/04 ,  A61K31/437 ,  A61K31/506 ,  A61K31/52 ,  A61K31/5377 ,  A61K31/538 ,  A61K45/06 ,  C07D487/04 ,  C07D519/00

Abstract: Derivatives of purine, 3H-imidazo[4,5-b]pyrimidine and 1H-imidazo[4,5-d]pyrazine of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.

Abstract translation: 抑制二酰基甘油酰基转移酶2（DGAT2）活性的式I的嘌呤衍生物，3H-咪唑并[4,5-b]嘧啶和1H-咪唑并[4,5-d]吡嗪及其在治疗疾病中的用途 本文描述了与动物相连的动物。

公开(公告)号：US20180207100A1

公开(公告)日：2018-07-26

申请号：US15578410

申请日：2016-05-24

Applicant: PFIZER INC.

Inventor： Fady Makram Louiz Ibrahim ,  Matthew Patrick Mullarney ,  Ravi M. Shanker ,  Barbara Rodriguez Spong ,  Jian Wang

IPC: A61K9/20 ,  A61K31/519 ,  A61K9/28

CPC classification number: A61K9/2013 ,  A61K9/2009 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/205 ,  A61K9/2054 ,  A61K9/2086 ,  A61K9/2095 ,  A61K9/28 ,  A61K31/4439 ,  A61K31/519 ,  A61K47/12 ,  A61K2300/00

Abstract: The present invention relates to solid dosage forms of palbociclib comprising a water-soluble acid. The dosage forms described herein have desirable pharmacokinetic characteristics.

公开(公告)号：US11065250B2

公开(公告)日：2021-07-20

申请号：US15578410

申请日：2016-05-24

Applicant: PFIZER INC.

Inventor： Fady Makram Louiz Ibrahim ,  Matthew Patrick Mullarney ,  Ravi M. Shanker ,  Barbara Rodriguez Spong ,  Jian Wang

IPC: A61K31/519 ,  A61K9/20 ,  A61K9/28 ,  A61K47/12 ,  A61K31/4439

Abstract: The present invention relates to solid dosage forms of palbociclib comprising a water-soluble acid. The dosage forms described herein have desirable pharmacokinetic characteristics.